Triple
T22405127
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Working Group of Registrars |
E553860
|
entity |
| Predicate | operatesUnder |
P86
|
FINISHED |
| Object | Heads of Medicines Agencies framework |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Heads of Medicines Agencies framework | Statement: [Working Group of Registrars, operatesUnder, Heads of Medicines Agencies framework]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Heads of Medicines Agencies framework Context triple: [Working Group of Registrars, operatesUnder, Heads of Medicines Agencies framework]
-
A.
Heads of Medicines Agencies
chosen
Heads of Medicines Agencies is a European network of national medicines regulatory authorities that collaborates to coordinate and harmonize the regulation of medicinal products across EU and EEA member states.
-
B.
Conditional Marketing Authorization by European Medicines Agency
Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
-
C.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
D.
WHO Collaborating Centre for Drug Statistics Methodology
The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
-
E.
European medicines regulatory authorities
European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e11e4da7048190b4387d422a9a0de5 |
completed | April 16, 2026, 5:37 p.m. |
| NER | Named-entity recognition | batch_69f158b739b88190a7f1f20fd1e9b188 |
completed | April 29, 2026, 1:02 a.m. |
Created at: April 16, 2026, 8:46 p.m.